Literature DB >> 1318261

Discovery of a genetic polymorphism of human plasma protein C inhibitor (PCI): genetic survey utilizing isoelectric focusing followed by immunoblotting, immunological and biochemical characterization.

T Yasuda1, D Nadano, R Iida, Y Tanaka, M Nakanaga, K Kishi.   

Abstract

The objectives of this study were to determine the genetic basis of the electrophoretic differences of human plasma protein C inhibitors (PCI) from 977 individuals. Three discrete antibodies were produced against the PCI purified from human plasma and peptides that corresponded to the N-terminal 15 amino acid residues and the C-terminal 15 residues of human PCI, the chemical structures of which were determined by cDNA sequence analysis. The combined techniques of polyacrylamide gel isoelectric focusing and immunoblotting with these three different antibodies resolved the plasma PCI into several isoprotein bands, with a pH range of 6-7. These PCI isoproteins, however, were not stained by anti-human kallikrein, anti-human protein C or anti-human urokinase antibodies. Therefore, each of the PCI bands, which were detected by immunoblotting with the anti-PCI antibody and the two different anti-peptide antibodies, were derived from free PCI, and not an inactive PCI species. Two common phenotypes, designated PCI 1 and 1-2, were recognized, and family studies showed that they represented homozygosity or heterozygosity for two autosomal codominant alleles, PCI*1 and PCI*2. A population study of plasma samples collected from 977 Japanese individuals indicated that the frequencies of the PCI*1 and PCI*2 alleles were 0.988 and 0.012, respectively.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1318261     DOI: 10.1007/bf00220537

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  26 in total

1.  Biochemical and genetic studies on GP43, a 43-kD glycoprotein detected immunologically in human urine and serum.

Authors:  K Mizuta; T Yasuda; K Kishi
Journal:  Biochem Genet       Date:  1989-12       Impact factor: 1.890

2.  New genetic markers detected in human urine: DNase I, RNase 1, and 43-kDa glycoprotein.

Authors:  K Kishi; T Yasuda; K Mizuta
Journal:  Prog Clin Biol Res       Date:  1990

3.  Human serum deoxyribonuclease I (DNase I) polymorphism: pattern similarities among isozymes from serum, urine, kidney, liver, and pancreas.

Authors:  K Kishi; T Yasuda; Y Ikehara; K Sawazaki; W Sato; R Iida
Journal:  Am J Hum Genet       Date:  1990-07       Impact factor: 11.025

4.  Newly characterized genetic polymorphism of uropepsinogen group A (PGA) using both isoelectric focusing and immunoblotting.

Authors:  K Kishi; T Yasuda
Journal:  Hum Genet       Date:  1987-03       Impact factor: 4.132

5.  Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor.

Authors:  J C Meijers; D H Kanters; R A Vlooswijk; H E van Erp; M Hessing; B N Bouma
Journal:  Biochemistry       Date:  1988-06-14       Impact factor: 3.162

6.  Protein C inhibitor: purification and proteinase reactivity.

Authors:  C W Pratt; B G Macik; F C Church
Journal:  Thromb Res       Date:  1989-03-15       Impact factor: 3.944

7.  Determination of functional and antigenic protein C inhibitor and its complexes with activated protein C in plasma by ELISA's.

Authors:  F España; J H Griffin
Journal:  Thromb Res       Date:  1989-09-15       Impact factor: 3.944

8.  Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease.

Authors:  R A Marlar; J H Griffin
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

9.  Inhibition of urokinase by protein C-inhibitor (PCI). Evidence for identity of PCI and plasminogen activator inhibitor 3.

Authors:  T W Stief; K P Radtke; N Heimburger
Journal:  Biol Chem Hoppe Seyler       Date:  1987-10

10.  Activation and complexation of protein C and cleavage and decrease of protein S in plasma of patients with intravascular coagulation.

Authors:  M J Heeb; D Mosher; J H Griffin
Journal:  Blood       Date:  1989-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.